Stephen Liu, MD
The development of next-generation tyrosine kinase inhibitors (TKIs) has led to deep and durable responses in patients with EGFR-mutant non–small cell lung cancer, but these agents have added to the complexity of acquired resistance mechanisms, said Stephen Liu, MD.
in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.
OncLive: What are the updates in EGFR-mutant and ALK-rearranged disease beyond frontline treatment?
We're familiar with EGFR
as actionable subsets within NSCLC. We've become much more comfortable with using targeted therapies in those settings. This year, we saw the publication of 2 large randomized phase III trials that showed the newer-generation drugs are more effective than the older ones, which gives us preferred and more effective treatments. What we are struggling with now is resistance and what to do when those drugs stop working.
... to read the full story